Antitumor immunotherapy for colorectal cancer has been studied at the bench and bedside
for decades. Some clinical trials of cancer immunotherapy have demonstrated a potential …

Modulation of the interaction between the immune system and the tumor microenvironment
has long been a target of cancer research, including colorectal cancer (CRC). Approaches …

Immunogenic cell death is characterized by the emission of danger signals that facilitate
activation of an adaptive immune response against dead-cell antigens. In the case of cancer …

This paper addresses the challenge of using non-equilibrium plasma as a therapeutic
approach for diseases of body systems not readily accessible to plasma-generated factors …

Intestinal enteroendocrine cells are critical to central regulation of caloric consumption, since
they activate hypothalamic circuits that decrease appetite and thereby restrict meal size by …

BACKGROUND & AIMS: GUCY2C is the intestinal receptor for the paracrine hormones
guanylin and uroguanylin that converts guanosine-5′-triphosphate to cyclic guanosine …

The search for a safe and efficacious vaccine for Ebola virus continues, as no current
vaccine candidate is nearing licensure. We have developed (i) replication-competent,(ii) …

Adoptive T-cell therapy (ACT) is an emerging paradigm in which T cells are genetically
modified to target cancer-associated antigens and eradicate tumors. However, challenges …

The Gram-positive bacterium Listeria monocytogenes (Lm) is an emerging platform for
cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm cancer …

Background The colorectal cancer antigen GUCY2C exhibits unique split tolerance, evoking
antigen-specific CD8+, but not CD4+, T-cell responses that deliver anti-tumor immunity …